Page last updated: 2024-11-05

nicotinyl alcohol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nicotinyl alcohol, also known as 3-pyridylmethanol, is a heterocyclic organic compound that serves as a building block for the synthesis of various pharmaceuticals and agrochemicals. It exhibits significant biological activity, acting as a potential anti-inflammatory agent and exhibiting antioxidant properties. Research on nicotinyl alcohol focuses on its potential therapeutic applications in treating inflammatory conditions and oxidative stress-related diseases. Its synthesis involves reduction of nicotinic acid, which is a readily available and inexpensive starting material. Further investigation into the detailed mechanisms of action and pharmacological profile of nicotinyl alcohol is crucial for its future development as a therapeutic agent.'

Nicotinyl Alcohol: Alcohol analog of NICOTINIC ACID which is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It is used in vasospasm and threatened GANGRENE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-pyridinemethanol : A member of the class of pyridines that is pyridine which is substituted by a hydroxymethyl group at position 3 . [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7510
CHEMBL ID1235535
CHEBI ID45213
SCHEMBL ID9853210
SCHEMBL ID16266
MeSH IDM0014841

Synonyms (125)

Synonym
AC-15599
HMS3394G07
nicotinyl alcohol (pyridylcarbinol)
ro-15155
CHEMBL1235535
c10ad05
smr000059086
MLS000028906
pyridin-3-ylmethanol
3-hydroxymethylpyridine
beta-picolyl alcohol
brn 0107851
nicotinyl alcohol [usan:ban]
einecs 202-864-6
3-picolyl alcohol
nsc 526046
beta-pyridinecarbinol
roniacol (tn)
nicotinyl alcohol (usan)
D05158
3-(hydroxymethyl)pyridine
nsc526046
3-pyridylmethanol
pyridyl-3-carbinol
100-55-0
3-pyridylcarbinol
nu 2121
pyridyl-3-methanol
pyridine-3-carbinol
3-pyridinylmethanol
nicotinic alcohol
nu-2121
.beta.-pyridylcarbinol
3-pyridinemethanol
ro-1-5155
ro 1-5155
niltuvin (free base)
.beta.-pyridinecarbinol
roniacol
nsc-526046
nicotinyl alcohol
.beta.-picolyl alcohol
inchi=1/c6h7no/c8-5-6-2-1-3-7-4-6/h1-4,8h,5h
MLS001424215
3-pyridinylcarbinol
3-pyridinemethanol, 98%
NCGC00159400-02
pyridine-3-methanol
pyridylmethanol
NCGC00159400-03
beta-pyridylcarbinol
pyridylcarbinol
DB04145
NCGC00159400-04
HMS2052G07
SCHEMBL9853210
P0555
AKOS000119474
NCGC00159400-05
NCGC00159400-06
unii-9tf312056y
9tf312056y ,
5-21-02-00172 (beilstein handbook reference)
pyridin-3-yl-methanol
3-pyridylmethan-1-ol
NCGC00257521-01
cas-100-55-0
tox21_300839
tox21_113448
dtxcid503367
dtxsid6023367 ,
3-pyridyl carbinol
?-hydroxy-3-picoline
HMS2232J07
AM802808
CCG-101090
(pyridin-3-yl)methanol
bdbm92860
pnca inhibitor, 4
FT-0674186
FT-0674210
HMS3372K15
nicotinyl alcohol [inci]
nicotinyl alcohol [who-dd]
nicotinyl alcohol [mart.]
nicotinyl alcohol [mi]
nicotinyl alcohol [usan]
NC00340
SCHEMBL16266
tox21_113448_1
NCGC00159400-07
FG-0435
CS-4356
3-pyridylmethyl alcohol
3-(hydroxymethyl)-pyridine
3-pyridyl methanol
pyridin-3-yl methanol
3-pyridinyl carbinol
3-pyridine methanol
3-hydroxymethyl pyridine
3-hydroxymethyl-pyridine
3-pyridyl-carbinol
J-650089
STR00172
ronicol (salt/mix)
W-108954
HY-B0893
AB00053787_07
(3-pyridyl)methyl alcohol
mfcd00006407
F0001-0022
3-pyridinemethanol, analytical standard
P16746
3-pyridinemethanol, vetec(tm) reagent grade, 98%
SBI-0052904.P002
3-pyridinemthanol
SY001086
CHEBI:45213
pyridine 3-methanol
omega-hydroxy-3-picoline
BCP20084
Q411732
nicotinyl-alcohol-tartrate
EN300-21373
Z104495622

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic parameters of fluoride have been studied, after a single oral administration to human volunteers of two fluoridated compounds: sodium fluoride, and a new organic fluoride salt, nicomethanol hydrofluoride."( [Blood pharmacokinetics of fluorine in man after the oral administration of nicomethanol hydrofluoride].
Cheymol, G; Mahuzier, G; Poitou, P; Souleau, M, 1984
)
0.27

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"Clofibrate and m-Inositolnicotinate in a daily dosage of 1,5 g Clofibrate and 1,2 g m-Inositolnicotinate during long term treatment effected a good triglyceride fall in all three lipoprotein fractions, especially in VLDL."( [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
Schwartzkopff, W; Zschiedrich, M, 1978
)
0.26
" Allopurinol at higher dosage diminished the noradrenaline-induced decrease of heart rate and increase of blood pressure."( [Effect of allopurinol on adrenergically induced changes in serum lipid levels, heart rate and blood pressure in normal and ischemic rabbits (author's transl)].
Förster, W; Lohse, M; Riedel, H; Sziegoleit, W, 1982
)
0.26
" A glucuronide conjugate of N-(3,5-dichlorophenyl)-2-hydroxysuccinamic acid (2-NDHSA) was identified in the urine from a rat dosed with [14C]NDPS."( Determination of the site of glucuronidation in an N-(3,5-dichlorophenyl)succinimide metabolite by electrospray ionization tandem mass spectrometry following derivatization to picolinyl esters.
Cui, D; Harvison, PJ, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
aromatic primary alcoholAny primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.08920.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency32.27740.000714.592883.7951AID1259369; AID1259392
cytochrome P450 2D6Homo sapiens (human)Potency34.67130.00108.379861.1304AID1645840
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency30.10650.057821.109761.2679AID1159526
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1124402Hypoglycemic activity in 48 hrs fasted Charles River rat at 150 mg/kg, po measured at 4 hrs relative to control1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthesis and hypoglycemic activity of pyridyl alcohols.
AID1124394Hypoglycemic activity in 48 hrs fasted Charles River rat at 150 mg/kg, po measured at 1 hr relative to control1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthesis and hypoglycemic activity of pyridyl alcohols.
AID1124398Hypoglycemic activity in 48 hrs fasted Charles River rat at 150 mg/kg, po measured at 2 hrs relative to control1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Synthesis and hypoglycemic activity of pyridyl alcohols.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1799845Enzyme Assay from Article 10.1021/bi1011157: \\Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.\\2010Biochemistry, Nov-09, Volume: 49, Issue:44
Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (166)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990136 (81.93)18.7374
1990's6 (3.61)18.2507
2000's4 (2.41)29.6817
2010's13 (7.83)24.3611
2020's7 (4.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.68 (24.57)
Research Supply Index5.28 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index38.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (9.50%)5.53%
Reviews7 (3.91%)6.00%
Case Studies5 (2.79%)4.05%
Observational0 (0.00%)0.25%
Other150 (83.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]